A 15 Week, Phase 2, Double Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Efficacy, Safety and Tolerability of PF 06649751 in Subjects with Motor Fluctuations due to PD
Clinical Trial Grant
Administered By
Neurology, Movement Disorders
Awarded By
Pfizer, Inc.
Start Date
July 1, 2016
End Date
December 31, 2018
Administered By
Neurology, Movement Disorders
Awarded By
Pfizer, Inc.
Start Date
July 1, 2016
End Date
December 31, 2018